Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas

Adult Glioblastoma Clinical Trial

Official title: Early Response Assessment Using on 3T Advanced MR Imaging as Predictor of Long-term Treatment Response in Newly Diagnosed Glioblastomas

Status Recruiting

Clinical Trial Summary

This clinical trial studies advanced MR imaging techniques in measuring early response of standard treatment may become predictors of long-term treatment response in patients with newly diagnosed glioblastomas.

Clinical Trial Description

The standard care of patients with glioblastoma is concomitant chemoradiation and adjuvant temozolomide. Allowing for assessment of tumor therapy prior to treatment completion is important to select patients most likely to benefit from alternative treatment option. Multimodal advanced MR imaging- contrast-enhanced T1 weighted imaging, diffusion-weighted imaging, chemical exchange saturation transfer imaging, and perfusion imaging on 3T enables quantitative assessment of treatment response. Quantifying changes in advanced MR imaging techniques would allow predict outcome for early and long-term treatment response and survival in glioblastomas. ;

Related Conditions & MeSH terms

• Adult Glioblastoma
• Glioblastoma

• NCT number: NCT02613988
• Study type: Interventional
• Source: Asan Medical Center
• Contact: Ho Sung Kim, MD, PhD
• Phone: +82230105682
• Email: radhskim@gmail.com
• Status: Recruiting
• Phase: N/A
• Start date: January 12, 2020
• Completion date: December 2025